WHAT IS CLAIMED IS:

1. A method of treating a depressive disorder in a human in need thereof, comprising administering a therapeutically effective amount of Compound A to the human;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

2. The method of claim 1, wherein the method comprises enhancing the opening of a Kv7 potassium channel in the human.

3. A method of enhancing the opening of a Kv7 potassium channel in a human, comprising administering an effective amount of Compound A to the human;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide; and

wherein the human has a depressive disorder.

4. The method of claim 2 or claim 3, wherein the Kv7 potassium channel is one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5.

5. The method of claim 4, wherein the method is selective for enhancing the opening of one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5 over Kv7.1.

6. The method of claim 2, wherein the method comprises opening of the Kv7.2/Kv7.3 (KCNQ2/3) potassium channel.

7. The method of any one of claims 1-6, wherein the depressive disorder is major depressive disorder (MDD), disruptive mood dysregulation disorder, persistent depressive disorder, bipolar spectrum disorder, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), atypical depression, treatment-resistant depression (TRD), depression associated with agitation or anxiety, adjustment disorder with depressed mood, prolonged depressive reaction, or a combination thereof.

8. The method of any one of claims 1-7, wherein the depressive disorder is major depressive disorder (MDD).

9. The method of any one of claims 1-8, wherein Compound A is orally administered to the human.

10. The method of any one of claims 1-9, wherein Compound A is administered at a dose of 2 to 200 mg to the human.

11. The method of claim 10, wherein Compound A is administered at a dose of 2 to 100 mg to the human.

12. The method of claim 10, wherein Compound A is administered at a dose of 5 to 50 mg to the human.

13. The method of claim 10, wherein Compound A is administered at a dose of 10, 20, or 25 mg to the human.

14. The method of claim 10, wherein Compound A is administered at a dose of 20 mg to the human.

15. The method of any one of claims 1-9, wherein Compound A is administered at a dose of at least 20 mg to the human.

16. The method of claim 15, wherein Compound A is administered at a dose of at least 50 mg to the human.

17. The method of claim 15, wherein Compound A is administered at a dose of at least 100 mg to the human.

18. The method of any one of claims 1-9, wherein Compound A is administered at a dose of 5-1000 mg per day to the human.

19. The method of claim 18, wherein Compound A is administered at a dose of 5-500 mg per day to the human.

20. The method of claim 18, wherein Compound A is administered at a dose of 5-250 mg per day to the human.

21. The method of claim 18, wherein Compound A is administered at a dose of 20-150 mg per day to the human.

22. The method of claim 18, wherein Compound A is administered at a dose of 100 mg per day to the human.

23. The method of any one of claims 1-22, wherein Compound A is administered at a dose of 0.05-2.0 mg/kg to the human.

24. The method of claim 23, wherein Compound A is administered at a dose of 0.1-1.0 mg/kg to the human.

25. The method of claim 23, wherein Compound A is administered at a dose of 0.2-0.5 mg/kg to the human.

26. Use of Compound A in the manufacture of a medicament for treating a depressive disorder in a human in need thereof;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.

27. The use of claim 26, wherein treating the depressive disorder comprises enhancing the opening of a Kv7 potassium channel in the human.

28. Use of Compound A in the manufacture of a medicament for enhancing the opening of a Kv7 potassium channel in a human;

wherein Compound A is *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide; and

wherein the human has a depressive disorder.

29. The use of claim 27 or claim 28, wherein the Kv7 potassium channel is one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5.

30. The use of claim 29, wherein enhancing the opening of a Kv7 potassium channel is selective for enhancing the opening of one or more of Kv7.2, Kv7.3, Kv7.4, or Kv7.5 over Kv7.1.

31. The use of claim 27, wherein enhancing the opening of a Kv7 potassium channel comprises opening of the Kv7.2/Kv7.3 (KCNQ2/3) potassium channel.

32. The use of any one of claims 26-31, wherein the depressive disorder is major depressive disorder (MDD), disruptive mood dysregulation disorder, persistent depressive disorder, bipolar spectrum disorder, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), atypical depression, treatment-resistant depression (TRD), depression associated with agitation or anxiety, adjustment disorder with depressed mood, prolonged depressive reaction, or a combination thereof.

33. The use of any one of claims 26-32, wherein the depressive disorder is major depressive disorder (MDD).

34. The use of any one of claims 26-33, wherein Compound A is orally administered to the human.

35. The use of any one of claims 26-34, wherein Compound A is administered at a dose of 2 to 200 mg to the human.

36. The use of claim 35, wherein Compound A is administered at a dose of 2 to 100 mg to the human.

37. The use of claim 35, wherein Compound A is administered at a dose of 5 to 50 mg to the human.

38. The use of claim 35, wherein Compound A is administered at a dose of 10, 20, or 25 mg to the human.

39. The use of claim 35, wherein Compound A is administered at a dose of 20 mg to the human.

40. The use of any one of claims 26-34, wherein Compound A is administered at a dose of at least 20 mg to the human.

41. The use of claim 40, wherein Compound A is administered at a dose of at least 50 mg to the human.

42. The use of claim 40, wherein Compound A is administered at a dose of at least 100 mg to the human.

43. The use of any one of claims 26-34, wherein Compound A is administered at a dose of 5-1000 mg per day to the human.

44. The use of claim 43, wherein Compound A is administered at a dose of 5-500 mg per day to the human.

45. The use of claim 43, wherein Compound A is administered at a dose of 5-250 mg per day to the human.

46. The use of claim 43, wherein Compound A is administered at a dose of 20-150 mg per day to the human.

47. The use of claim 43, wherein Compound A is administered at a dose of 100 mg per day to the human.

48. The use of any one of claims 26-47, wherein Compound A is administered at a dose of 0.05-2.0 mg/kg to the human.

49. The use of claim 48, wherein Compound A is administered at a dose of 0.1-1.0 mg/kg to the human.

50. The use of claim 48, wherein Compound A is administered at a dose of 0.2-0.5 mg/kg to the human.